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Toll-like receptors (TLRs) belong to a class of molecules known as pattern recognition receptors, and they are part of the innate
immune system, although they modulate mechanisms that impact the development of adaptive immune responses. Several studies
have shown that TLRs, and their intracellular signalling components, constitute an important cellular pathway mediating the
inﬂammatory process. Moreover, their critical role in the regulation of tissue injury and wound healing process as well as in the
regulation of apoptosis is well established. However, interest in the role of these receptors in cancer development and progression
hasbeenincreasingoverthelastyears.TLRsarelikelycandidatestomediateeﬀectsoftheinnateimmunesystemwithinthetumour
microenvironment. A rapidly expanding area of research regarding the expression and function of TLRs in cancer cells and its
association with chemoresistance and tumourigenesis, and TLR-based therapy as potential immunotherapy in cancer treatment is
taking place over the last years.
1.Introduction
Toll-like receptors (TLRs) are a family of transmembrane
receptors that play a key role in the nonspeciﬁc or innate
immune defense, particularly in inﬂammatory response
against various invading exogenous pathogens, by recognis-
ingreceptor-speciﬁcpathogen-associatedmolecularpatterns
of highly conserved pathogenic components of bacteria,
viruses, fungi, and parasites [1]. Once these pathogens have
breached physical barriers such as the skin or intestinal
tract mucosa, they are recognized by TLRs which activate
immune cell responses against their structurally conserved
molecules. The most important role of TLRs in host defense
is the regulation of innate and adaptive immune responses
by epithelial cells, the ﬁrst line of defense at mucosal sites
such as the respiratory, genitourinary, and gastrointestinal
tracts,andtheskin.TLRsalsohaveacrucialroleinmediating
leukocyte recruitment to infected tissues and the uptake
of microorganisms by phagocytic cells [2, 3]. Activation
of antigen-presenting cells (APCs) such as dendritic cells
(DCs) and stimulation of both T- and B-cell-mediated
immune responses are due mostly to ligation of TLRs
[4].
Moreover, TLRs have an important role in maintaining
tissue homeostasis by regulating tissue repair and regen-
eration. TLR ligands in this case can be either microbial
(exogenous) or host derived (endogenous) [5]. In addition,
TLR signalling has also been shown to regulate apoptosis
with the expression of antiapoptotic proteins or inhibitors of
apoptosis.
They derive their name from their similarity to the
protein coded by the Toll gene identiﬁed in Drosophila
in 1985 by Christiane N¨ usslein-Volhard [6]. The human
TLR family consists of currently ten members, which are
structurally characterized by the presence of a leucine-rich
repeat (LRR) domain in their extracellular domain and
a Toll/Interleukin (IL)-1 receptor (TIR) domain in their
intracellular domain [7]. Epidemiologic studies of the many
single nucleotide polymorphisms that have been identiﬁed
in various TLR genes have been studied in relationship
to tumourigenesis. Studies of common genetic variants in
various populations and growth stimulation of cancer cell
lines suggest that TLR4 plays an important role in the
development of H. pylori-associated gastric cancer [8, 9].
Other studies have found that common polymorphisms
in TLR2 are associated with increased risk of colorectal2 Mediators of Inﬂammation
cancer [10], gastric cancer [11] and lymphoma [12], while
a speciﬁc haplotype in TLR10 is associated with increased
risk of nasopharyngeal cancer [13]. A recent study revealed
a signiﬁcant association of a common genetic variant within
the TLR10-TLR1-TLR6 gene cluster with decreased risk of
initial development of prostate cancer [14].
The relationship between inﬂammation and tumourige-
nesis and tumour progression is widely accepted. Numerous
studies have provided convincing evidence that bacterial-
and viral-induced inﬂammatory process can mediate
tumourigenesis. Moreover, it is well known that regular
intake of nonsteroidal antiinﬂammatory drugs lowers the
risk of developing some types of cancer.
Due to the important role in inﬂammation and tissue
regeneration, TLRs are likely candidates to mediate eﬀects
of the innate immune system on tumourigenesis. TLR
expression and function in cancer cells and its association
with the inﬂammation process and tumourigenesis will be
discussed here.
2.Toll-LikeReceptorsSignallingPathways
TLRs belong to a class of molecules known as pattern recog-
nition receptors. The ligands for these receptors are compo-
nents of pathogenic microbes and are often called pathogen-
associated molecular patterns (PAMPs). The recognition of
PAMPs by TLRs is a cornerstone of innate immunity and
provides a quick and highly eﬃcient response to pathogens
in both vertebrate and invertebrate species [15]. In addition
to recognizing ligands derived from foreign microbes TLRs,
in particular TLR2 and TLR4 have been reported to bind
numerous endogenous ligands termed damage-associated
molecular patterns (DAMPs) that are released from injured
and inﬂamed tissue [5]. Thus, the TLR-mediated immune
responsemaybeactivatedintheabsenceofforeignmicrobes.
Upon binding of a microbial ligand, TLRs activate signalling
pathways that stimulate cytokine production and other parts
of the innate immune response. Well-known TLR microbial
ligands are lipopolysaccharide (LPS), a membrane com-
ponent of Gram-negative bacteria, bacterial lipoproteins,
lipoteichoic acid and fungal zymosan, bacterial ﬂagellin,
double-stranded RNA, and single stranded RNA. TLR4
senses Gram-negative bacteria by binding LPS. Bacterial
lipopeptides and lipoteichoic acids (LTAs) stimulate TLR2
responses.TLR3andTLR7senseviralinfectionsbyrecogniz-
ing double-stranded and single-stranded RNA, respectively.
TLR9 recognizes nonmethylated CpG-containing DNA from
bacteria and viruses.
TLRs that mainly serve to detect bacterial LPS and
lipoproteins are located on the cell surface (TLR1, TLR2,
and TLR4-6) whereas those that mainly recognize viral RNA
and bacterial DNA are located in late endosome-lysosomes
in which these materials are processed (TLR3, TLR7, TLR8,
and TLR9). TLR1, TLR2, TLR4, and TLR6 initiate signalling
by heterodimerization. TLR2 forms heterodimers with TLR1
or TLR6 which recognize bacterial triacylated and diacylated
lipoproteins, respectively [7]. A wide range of DAMPs
including heat shock proteins, high-mobility group box 1
(HMGB1), uric acid crystals, hyaluronan, heparin sulfate,
messenger RNA, surfactant protein A, and various products
of the extracellular matrix such as ﬁbronectin and ﬁbrinogen
have been suggested to activate TLRs [16, 17].
After ligation of TLR ligands, TLRs dimerize and
transmit signals throughout the cell through one or more
of four adaptor proteins: myeloid diﬀerentiation primary
response gene 88 (MyD88), toll/interleukin-1-receptor-
domain-containing adaptor inducing interferon-β (TRIF),
toll/interleukin-1-receptor-domain-containing adaptor pro-
tein (TIRAP), and TRIF-related adaptor molecule (TRAM).
Whereas MyD88 is part of the signalling cascade of all TLRs
except for TLR3, TRIF only interacts with TLR3 and TLR4
(Figure 1).
TLR2 or TLR4 agonists stimulate the MyD88 signaling
pathway in APCs such as macrophages and DC, which
leads to subsequent downstream activation of the major
transcription factors, the nuclear factor of kappa light
polypeptide gene enhancer in B-cells (NF-κB) and mitogen-
associated protein (MAP) kinase signaling pathways (such
as the ERK-CREB pathway, the JNK-AP1 pathway, and
the p38 pathways) [18]. This leads to the rapid expression
of inducible nitric oxide synthase (iNOS) and a wide
variety of proinﬂammatory cytokines, chemokines, and their
receptors, including tumor necrosis factor alpha (TNF-α),
interleukin (IL)-1α,I L - 1 β, IL-1ra, IL-6, IL-8, IL-10, IL-
12p40, IL-23, and macrophage inﬂammatory protein (MIP)-
1α,a n dM I P - 1 β (Figure 2)[ 19, 20]. These factors initiate
the inﬂammatory response, increase vascular permeability,
direct DC and macrophage migration from the periphery to
the central lymphoid organs, and regulate various aspects of
adaptive immunity development.
Recently, naturally arising regulatory T-cells (Tregs) have
beenshowntoexpressTLRs.Tregsoriginatefromthethymus
and are characterized by the expression of Foxp3 as a key
control gene for their development and function. Their
pivotal role is maintaining immunological self-tolerance.
Recent data suggest that the activation of TLRs on Tregs can
increase or decrease their suppressive activity, thus providing
an important link between innate and adaptive immune
responses [21]. Milkova et al. suggested an important role
of the NF-κB signalling pathway for the induction and
modulation of suppressive function of Tregs, if they are
confronted with TLR4 ligands such as LPS [22].
3.Toll-Like Receptors,TissueRepair,
and Fibrogenesis
The tissue repair and regeneration process has been reported
to depend on MyD88 signalling. The importance of this
signalling pathway has been demonstrated by a recent study
which showed that wound healing was impaired in MyD88-
deﬁcient mice [23]. MyD88 is a critical signal adaptor for
TLRs2,4,5,7,8,9,and11whereasTLR3signalsinaM yD88-
independent manner through the TRIF adapter pathway.
TLR activation in wound healing appears to be mediated
by two entirely diﬀerent classes of ligands: (1) in organs that
are in direct contact with microbiota (intestine, skin, liver),Mediators of Inﬂammation 3
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Figure 1: Toll-like receptor (TLR) signalling pathways. Membranal TLRs (represented by TLR4) recognize external ligands (exogenous and
endogenous), while cytoplasmic TLRs (TLR3) recognize intracellular signals. When activated, the majority of TLRs induce activation of
NF-κB (early phase of NF-κB activation) and cytokine production in a MyD88-dependent manner; while TLR4, like TLR3, can also signal in
a MyD88-independent manner and induce the expression of type I interferons (IFN) and IFN-inducible proteins in addition to a late phase
NF-κB activation.
tissue injury leads to a breakdown of protective barriers and
subsequent TLR activation by bacterial PAMPs. (2) In many
organs such as liver, heart, and kidney, tissue injury leads to
release of DAMPs from dead and dying cells resulting in the
activation of TLRs and “sterile inﬂammation.” The release of
endogenous TLR ligands predominantly occurs aftermassive
tissue injury, especially where a signiﬁcant percentage of cells
undergo necrosis such as in ischaemia-reperfusion injury.
Activation of TLRs modiﬁes tissue injury in positive or
negative fashion either by recruiting inﬂammatory cells that
release cytotoxic mediators or by activating cytoprotective
signals. TLRs exert a cytoprotective role and prevent tissue
injury in the lung and the intestine. In bleomycin-induced
lung injury, TLR2-TLR4- and MyD88-deﬁcient mice display
an increased degree of lung injury despite reduced recruit-
ment of inﬂammatory cells. Jiang et al. showed that by
blocking the endogenous ligand hyaluronan by a peptide-
based approach, the pattern of lung injury was highly similar
to that of MyD88 and TLR2-TLR4-deﬁcient mice [24].
In contrast, ischaemia-reperfusion injury represents the
scenario in which a profound injury-promoting role of
TLR2 and TLR4 has been most thoroughly established.
Several studies have shown the protection of TLR4-mutant
or deﬁcient mice after hepatic and cardiac ischaemia-
reperfusion [25, 26]. DCs are the most likely candidate
to mediate injury following ischemia-reperfusion injury.
After hepatic ischemia-reperfusion, wild-type but not TLR4-
mutant dendritic cells displayed a strong increase of TNF-
α production [27], a well-known mediator of hepatic
ischemia-reperfusion injury that is rapidly and potently
releasedfrommacrophagesandDCfollowingTLRactivation
[28,29].Therefore,themostlikelyscenarioisthatHMGB1is
released from necrotic parenchymal cells to activate TLR4 on
D Cw h i c hi nt u r nr e l e a s e sT N F - α to promote tissue injury.
TLR receptors are also involved in the regulation of
epithelial proliferation and angiogenesis following injury.
TLR4- and MyD88-dependent signals following dextran
sulfate sodium-(DSS-) mediated colonic injury, are required
to induce cyclooxygenase 2-(Cox2-) mediated generation of
prostaglandin E2 (PGE2) and to stimulate epithelial cell
proliferation [30]. The MyD88-Cox2 signal that promotes
regeneration is largely provided by macrophages which
migrate toward the site of injury to stimulate the prolifera-
tion of epithelial progenitors. PGE2 is one crucial growth-
promoting signal provided by stimulated macrophages. The
mechanism for improved epithelial repair may be through4 Mediators of Inﬂammation
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Figure 2:Toll-likereceptor(TLR)signallingismediatedbyatleasttwodistinctpathways.Afterrecognitionofapathogen-speciﬁcmolecular
pattern, TLRs are capable of diﬀerentially activating distinct downstream signalling events via diﬀerent cofactors and adaptor proteins
mediating diverse immune responses [1]. The MyD88-dependent TLR signalling pathway is activated via the conserved, cytoplasmic
TIR domain, which provides a scaﬀold for recruitment of the adaptor molecule MyD88 and serine/threonine kinases of the IL-1R-
associated kinase (IRAK) family. Following IRAK autophosphorylation, the TRAF6 adaptor protein interacts and induces translocation of
the transcription factor NF-κB to the nucleus, resulting in transcriptional activation of genes encoding cytokines and chemokines (TNF-α,
NO, COX-2, SOCS (for “suppressor of cytokine signalling”), IP-10, IFN-b and IL-1, 6, 8, 10, 12). In addition, expression of proteins involved
in apoptosis and production of adherent and costimulative molecules such as ICAM1, occur. Moreover, TLRs bridge the signalling pathway
via ECSIT (for “evolutionarily conserved signalling intermediate in Toll pathways”) to TRAF6 for p42/p44 mitogen-activated protein kinase
(MAPK) kinase (MKK), p38, and JNK in response to speciﬁc bacterial products [2]. The MyD88-independent TLR signalling pathway is
activated via TIRAP and results in activation of the dsRNA-binding protein kinase PKR. This protein has been proposed to be a central
downstream component of both the TIRAP- and MyD88-dependent signalling pathways and could mediate potential crosstalk between
them. The MyD88-independent pathway appears to utilise both IFN-regulatory factor 3 (IRF3) and NF-κB, and results in the expression of
IFN-g-inducible genes including IP-10.
PGE2-dependent activation of epidermal growth factor
receptor (EGFR) [31]. The TLR4-MyD88 signaling axis is
also involved in the regulation of angiogenesis to restoring
blood ﬂow to the site of injured tissue. Promotion of
angiogenesis by TLR4 appears to be restricted to speciﬁc
pathophysiological circumstances. In skin wounds, absence
of MyD88 results in slower wound healing, decreased angio-
genesis, and decreased vascular endothelial growth factor
(VEGF) [23]. TLR4 activation alone is not suﬃcient for the
induction of VEGF, but requires the presence of adenosine,
and is largely mediated by a transcriptional upregulation of
HIF1α which binds to a known hypoxia response element in
the VEGF promoter [32].
Moreover, there is accumulating evidence that TLRs
directly target ﬁbroblasts to induce activating signals. One
main mechanism by which TLRs modulate ﬁbrogenic
responses is through the transforming growth factor beta
(TGF β) signaling pathway. In the liver, TLR4 and MyD88
are required for the development of ﬁbrosis in chronic
hepatitis. Activation of TLR4 sensitizes hepatic stellate cells,
the main precursor of ﬁbroblasts in the liver, toward the
eﬀects of TGFβ and thereby, promotes collagen production
[33]. This eﬀect is mediated by the downregulation of
an inhibitory TGFβ p s e u d o r e c e p t o r ,B a m b i .B a m b id o w n -
regulation is mediated through a MyD88-dependent and
TRIF-independent pathway [33]. In addition, TLRs promote
proinﬂammatory and antiapoptotic signals in ﬁbroblast
populations through NF-κB[ 34, 35].
4.Toll-Like ReceptorsandApoptosis
Toll-like receptors are potent activators of the NF-κB path-
way [4]. NF-κB regulates the transcription of a number of
antiapoptotic genes such as Bcl-2, iNOS, c-FLIP, inhibitor
of apoptosis (IAP), and TRAF molecules [36]. There is
increasing evidence that TLRs provide signals to promote
the survival of epithelial cells under stress conditions. It has
already been demonstrated that TLRs exert a cytoprotective
role in the lung and the intestine [24]. Additionally, TLR4-
MyD88-NF-κB-Cox2 axis is involved in protection fromMediators of Inﬂammation 5
apoptosis in normal as well as premalignant cells of the
colon [30]. Cox2 is a known mediator of antiapoptotic,
proliferative, and tumor-promoting eﬀects in the colon as
mentioned above [30].
Moreover, TLRs assist natural killers (NK) cells in the
killing of infected cells either by direct stimulation on
NK cells or the induction of type I interferons and IL-
15. Becker et al. found that Leishmania lipophosphoglycan
(LPG) activates NK cells through TLR2 [37].
5.Toll-Like Receptors andTumourigenesis
SeveralstudiesindicatethatTLRsignallingcontributestothe
growth of tumours in numerous organs. The development
of cancer has been associated with microbial infection,
injury, inﬂammation, and tissue repair. The subsequent
activation of TLRs in cancer cells and the ensuing sig-
nalling cascade with the cytokine/chemokine production
may promote cancer cell survival, chemoresistance and
therefore tumour progression. In a recent study, Huang
et al. reported the expression of TLR4 in murine tumour
cell lines and showed that the activation of TLR4 in these
tumour cells by LPS induced tumour evasion from immune
surveillance [38]. In another report it has been shown
that in a subgroup of epithelial ovarian cancer cells that
express MyD88, ligation of TLR4 by LPS induced cell
proliferation and enhanced cytokine/chemokine production
[39]. Huang et al. also showed that Listeria monocytogenes
promotes cell growth through TLR2 [40]. In 2007, He et al.
described the expression of TLR4 in human lung cancer cells
[41]. The direct promotion of cancer cell survival and the
inﬂammation-induced chemoresistance have been linked to
the hyperactivation of NF-κB in cancer cells, which induces
upregulation of antiapoptotic proteins such as c-FLIP and
XIAP, and inhibition of proapoptotic proteins such as Bax
and Caspase-9 [42, 43]. Another report showed that the
ligationofTLR2inlungcancercellsinducedtheactivationof
mitogen-activated protein kinases (MAPK) as well as NF-κB
w h i c hw e r es h o w nt op r o l o n gc a n c e rc e l ls u r v i v a l[ 40].
A number of recent studies have investigated carcino-
genesis in mice deﬁcient in TLRs or TLR adapter molecules
using models of inﬂammation-associated cancer. These
models provide a physiological tumour environment thus
accounting for a possible role of TLRs in stroma-tumour
interactions, possibly mediated by endogenous TLR ligands
released from necrotic tumour cells. TLR4-deﬁcient mice
display a profoundly reduced dysplasia, number and size of
tumours [44]. Similar results were reported in a study that
investigated the role of MyD88 in colon cancer. MyD88 deﬁ-
ciencyleadstodecreasedcarcinogenesisinnoninﬂammatory
model of colon cancer [45]. Additionally, the development
of ﬁbrosis-associated hepatocellular cancer in patients with
chronic hepatitis, it is likely that is promoted by the TLR-
MyD88 pathway [33].
Another interesting hypothesis is that cancer develop-
ment might be an abnormal form of tissue repair in which
the control mechanism loses its function. The presence of
deregulated infection, inﬂammation and/or tissue injury
as occurs during various stages of tumourigenesis, leads
to unregulated TLR-regulated tissue repair response [46].
MicroRNAs (miRNAs) are a class of small RNA molecules
that regulate gene expression at posttranscriptional level and
may function as either oncogenes or tumour suppressors.
Several studies have demonstrated a link between miRNAs
and TLR function, and therefore potential association with
inﬂammation and cancer formation. MiR-155, one of the
most studied miRNAs related to inﬂammation and cancer,
is highly expressed in B-cell lymphoma, breast and lung
cancers, and pancreatic adenocarcinomas. A recent study
showed that ligands for TLR2, TLR3, TLR4 and TLR9 could
all induce the upregulation of miR-155 expression, through
both MyD88- and TRIF-dependent pathways [47]. MiR-146
is highly expressed in breast, prostate, pancreatic, stomach
and papillary thyroid carcinomas, and is a target of NF-κB,
upregulated upon TLR2, TLR4 or TLR5 ligation [48].
6.Toll-Like Receptorsand
Tumour Microenvironment
The regulation of immune response within the tumour
microenvironment might be another consequence of TLR
activation. The inﬁltrating immune cells contribute to
cancer growth and metastasis. In a study on oral epithelial
squamous cell carcinoma it has been shown that the level
of immune cell inﬁltration was directly correlated with
the level of morphological and pathological transforma-
tion from normal to malignant phenotypes [49]. During
both cancer development and tissue repair process, the
immune inﬁltrate is characterized by the presence of a
high number of macrophages, which produce VEGF, IL-6,
IL-10, prostaglandins, iNOS, and IDO. Inﬂammatory cells,
primarily macrophages, are consistently regarded as critical
mediators involved in cancer initiation and promotion [50].
They facilitate angiogenesis and extracellular matrix break-
down and remodeling and promote cancer cell invasion.
The tumor stroma is made up of diverse cellular popu-
lations including macrophages, lymphocytes, vascular cells,
and carcinoma-associated ﬁbroblasts. Versican, a large extra-
cellular matrix proteoglycan, accumulates both in tumour
stroma and cancer cells. It participates in cell adhesion,
migration, and angiogenesis, all features of invasion and
metastasis. A recent study has documented that versican can
activate tumour-inﬁltrating myeloid cells through TLR2 and
its coreceptors TLR6 and CD14 and elicit the production of
proinﬂammatory cytokines including TNF-α that enhance
tumour metastasis [51]. The interaction between versican
and TLR2 links inﬂammation and metastasis.
As both resident ﬁbroblasts and endothelial cells (ECs)
also express functional TLR2 and its coreceptors, versican
may trigger the activation of both ﬁbroblasts and ECs, lead-
ing to a marked increase in interleukin-8 (IL-8) production
[52]. IL-8 is a proinﬂammatory chemokine with leukocyte
chemotactic, tumourigenic, and proangiogenic properties.
It increases proliferation and survival of endothelial and
cancer cells and enhances the migration of cancer cells, ECs,
and inﬁltrating neutrophils at tumor sites [53]. Interestingly,6 Mediators of Inﬂammation
ligation of TLR2 by versican appears to be directly involved
in the activation of multiple types of cells in tumour stroma,
including macrophages, and the induction of inﬂammatory
cytokine secretion to generate an inﬂammatory microenvi-
ronment hospitable for tumor progression [54].
7.Toll-Like Receptors andCancerTreatment
It was the original observation that certain cancer patients
who developed concurrent bacterial infections would also
experience concomitant remission of their malignant disease
[55]. It has been suggested that host molecules including
TNF, have implicated in the mediation of the antitumour
eﬀects of endotoxin [56]. However, subsequent testing
using recombinant TNF showed many of the toxicities of
endotoxin without however equaling the signiﬁcant antitu-
mour eﬃcacy in both clinical trials and laboratory studies.
AlthoughTNFfailedtomaterializetheantitumoureﬀect,the
identiﬁcation and production of several cytokines supplied
the dream of cancer immunologists. However, almost all of
several cytokines have been tested in animal tumor models,
but none has demonstrated similar antitumour eﬀects of
endotoxin, except one: IL-12. Taking into consideration the
close similarity of the antitumour characteristics between
endotoxin and IL-12, and the fact that endotoxin is able
to induce IL-12 production, it has been hypothesized that
endotoxin exerts its antitumour eﬀect through the induction
and the biological activity of IL-12. Interestingly, exposure
of DC to PAMPs like TLR ligands induces DC to produce
high levels of IL-12p70 and promote eﬃcient T-cell help
[55]. Murine studies also showed that only maturation with
TLR ligands generates mature DC enable to produce IL-
12 and promote optimal T-cell help [57]. In this regard,
it has recently demonstrated that a maturation cocktail
combining the TLR3 ligand polyinosinic-polycytidylic acid
(poly(I:C)) and the TLR7/8 ligand R848 supplemented with
PGE2 yields DC with both high migratory capacity and
IL-12p70 production upon T-cell encounter [58]. Whether
the vaccine-matured DC improves antitumour responses in
vivo is yet unknown but all these ﬁndings open new roads
concerning the role of TLRs in the treatment of neoplastic
diseases.
A recent study suggests that TLR4 and MyD88 play
an important role in antitumour responses following
chemotherapyandirradiation.TLR4-deﬁcientmicehavesig-
niﬁcantly larger tumours after doxorubicin and oxaliplatin
treatmentorirradiationthanwild-typemice[59].Datafrom
thisstudysuggeststhatcelldeathinductionbychemotherapy
or irradiation induces the release of HMGB1 to subsequently
triggerTLR4activationinDC,enhanceantigenpresentation,
and promote cytotoxic T-cell responses. The ability of TLR
signalling to activate the adaptive immune system has led
to attempts to harness this response against cancer cells
through the use exogenous administration of TLR ligands.
It has been shown that high doses of TLR agonists can
lead to apoptosis and directly kill both tumour cells and
ancillarycellsofthetumourmicroenvironment,whereaslow
doses of TLR agonists promote cancer growth [60]. TLR
activation may also cause tumours to regress by increasing
vascular permeability and by recruiting leukocytes, resulting
intumourlysisbyNKandcytotoxicTcells.InadditionTLRs
are important in the recognition of microbial pathogens
such as Epstein-Barr virus, hepatitis B and C viruses, human
papilloma virus, and Helicobacter pylori, all of which are
important aetiological agents of human cancers.
TLR2/4 agonists are promising molecules against
chemotherapy- or radiotherapy-relapsing tumours. TLR2/4
signalling produces TNF-α, which is required for inducing
DC maturation and migration [61]. Mature DC that reach
the lymph nodes induce a rapid and sustained congestion
of lymphocyte traﬃc and their number determines the
magnitude of T-cell proliferation and eﬀector response. In
this respect, helper T-cell 2 (Th2) immunity and antibody
responses may not be desirable in cancer where Th1
and cytotoxic T-cell responses are necessary [62]. TLR-
dependent cytokines play a pivotal role in the establishment
and maintenance of the Th1/Th2 balance, with IL-12
and IFN-γ committing cells to Th1 lineage diﬀerentiation
[52, 59]. An IFN-γ and IL-12 rich local environment attracts
T-cells to the tumor where the rich cytokine milieu promotes
the development of a CD4+ Th1 antitumor response that
eventually gives rise to cytotoxic CD8+ antitumor cell
response. Conversely, in the absence of IL-12 and IFN-γ,
IL-4 promotes Th2 development.
TLR2 and TLR4 agonists may diﬀer in their ability to
inﬂuence Th-cell proliferation [19, 63]. TLR2 preferentially
inducesIL-10,acytokinethatinhibitsthesynthesisofseveral
proinﬂammatory cytokines, and that belongs to the Th2
response in the mouse.
Conversely, the factors speciﬁcally induced by TLR4
(IP-10, IL-12, IL-15, and IFN-γ) are all associated with
a Th1 lineage commitment. But the picture is somewhat
complicated by the observation of Komai-Koma et al. that
TLR2 is expressed on activated T-cells as a costimulator for
antigen-speciﬁc T-cell development and participates in the
maintenance of T-cell memory [64].
Moreover, TLR2/4 signaling promotes iNOS-dependent
apoptosis of chemotherapy-resistant tumor cell clones. The
TLR2/4 agonist, OM-174 is a promising molecule against
cancer metastases. Studies in cancer patients showed that
intravenous OM-174 induces well-tolerated TNF-α secre-
tion, at plasma levels known to permeabilize neoangiogenic
tumour vessels to the passage of cytotoxic drugs [65].
Mycobacterium bovis bacillus Calmette-Guerin (BCG) is
another TLR2/4 agonist eﬀective against superﬁcial bladder
tumours [65]. OK-432, a penicillin-killed and lyophilized
preparation of a low-virulence strain of Streptococcus
pyogenes (group A), is a TLR4 agonist which has been
successfully used as an immunotherapeutic agent in many
types of malignancies, including head and neck cancer and
oral squamous cell carcinoma [66]. OK-432 polarizes the T-
cellresponsetoaTh1dominantstate.Tanoetal.showedthat
OK-PSA, an active component of OK-432, induces apoptosis
by the activation of caspases through p53-independent path-
way via TLR4 signaling in head and neck cancer cells [67].
Imiquimod, a synthetic agonist of TLR7 has been proven
very eﬀective as monotherapy for basal cell carcinoma, whenMediators of Inﬂammation 7
applied topically as a 5 percent cream [68]. It is also used in
the treatment of actinic keratoses and genital warts.
8. Conclusion
TLRs have emerged over the last decade as key regulators
of innate and adaptive immune responses. In addition, the
TLR pathways have been shown to play a critical role in
the regulation of tissue injury and wound healing process
as well as in the regulation of apoptosis. However, interest
in the role of these receptors in cancer has been increasing.
There is a large and growing body of literature exploring
associations of TLR biology with tumourigenesis. Common
polymorphisms in TLR genes have been associated with
increased risk for several types of cancer. TLR activation
and regulation of immune response within the tumour
microenvironment and the ensuing signaling cascade with
the cytokine/chemokine production may promote cancer
cell survival, chemoresistance, and therefore tumour pro-
gression. Moreover, the unregulated TLR-regulated tissue
repair response during various stages of tumourigenesis, and
the upregulation of several miRNAs through TLR ligation,
might explain the critical role of TLR pathways in cancer
progression. Alternatively, increasedTLRactivation byeither
microbial or endogenous ligands may stimulate anticancer
immunity.
Takenalltheaboveintoconsideration,targetingtheTLRs
with TLR agonists might be promising as eﬀective regimens
toﬁghtcancerandtoprolongsurvivalincancerpatientswho
relapse under chemotherapy. Thus, better understanding of
the function and regulation of the TLR signalling pathways
and further study of the eﬀect of TLR activation on cancer
cells are essential for the understanding of tumour initiation
and progression.
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